Summary
Dosing claim aligns with label 2.3 (80 mg once daily with or without food). However, the AI response omits critical safety-related labeling elements (boxed warnings, contraindications, pregnancy/pediatric use, drug interactions, and monitoring) which are required for full label alignment.
Category Scores
Accurate Statements
Dosing of TAGRISSO as 80 mg tablet orally once daily with or without food.
2.3: Recommended dosage confirms 80 mg once daily with or without food.
Unsupported Statements
Contradictions
Important Omissions
Boxed warning for interstitial lung disease (ILD)/pneumonitis not mentioned.
Importance:
High
Contraindications (if any) as listed in labeling not specified.
Importance:
High
Pregnancy and lactation risk information not included.
Importance:
High
Pediatric safety/effectiveness not addressed.
Importance:
Moderate
Drug interactions (e.g., CYP3A4) and monitoring guidance not provided.
Importance:
High
Monitoring parameters and dose modification guidance related to safety not provided.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Dosing claim is accurate; however, critical safety information is omitted.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Missing safety information
Suggested Improvement
Include complete on-label elements: boxed warnings, contraindications, pregnancy/lactation guidance, pediatric use, drug interactions, and monitoring guidance to achieve full label alignment.